{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T11:35:24Z","timestamp":1750073724703,"version":"3.40.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00192-024-06009-6","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T22:16:40Z","timestamp":1736029000000},"page":"567-574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Urodynamic Changes Following Fewer Injection Sites of Intravesical Botulinum Toxin in Idiopathic Detrusor Overactivity: A Double-Blinded Prospective Randomized Clinical Trial"],"prefix":"10.1007","volume":"36","author":[{"given":"Niloofar","family":"Soleimanifard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza Kaffash","family":"Nayeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehran","family":"Moghimian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0802-1872","authenticated-orcid":false,"given":"Sona","family":"Tayebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Emami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"issue":"1","key":"6009_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/nau.20870","volume":"29","author":"P Abrams","year":"2010","unstructured":"Abrams P, Andersson K-E, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth international consultation on incontinence recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213\u201340.","journal-title":"Neurourol Urodyn"},{"issue":"Suppl 1","key":"6009_CR2","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.4111\/icu.2020.61.S1.S33","volume":"61","author":"JL Chen","year":"2020","unstructured":"Chen JL, Kuo HC. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. Investig Clin Urol. 2020;61(Suppl 1):S33\u201342.","journal-title":"Investig Clin Urol"},{"issue":"15","key":"6009_CR3","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2174\/1389450121666200621194732","volume":"21","author":"A Apostolidis","year":"2020","unstructured":"Apostolidis A, Papaefstathiou E, Gatsos S. Intravesical Botox for overactive bladder: how to minimize complications and manage failures. Curr Drug Targets. 2020;21(15):1527\u201336.","journal-title":"Curr Drug Targets"},{"issue":"6","key":"6009_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"W Stewart","year":"2003","unstructured":"Stewart W, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327\u201336.","journal-title":"World J Urol"},{"issue":"5","key":"6009_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0090-4295(02)01784-3","volume":"60","author":"AJ Wein","year":"2002","unstructured":"Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002;60(5):7\u201312.","journal-title":"Urology"},{"issue":"4","key":"6009_CR6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.eururo.2008.04.037","volume":"56","author":"H-T Liu","year":"2009","unstructured":"Liu H-T, Chancellor MB, Kuo H-C. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol. 2009;56(4):700\u20137.","journal-title":"Eur Urol"},{"issue":"3","key":"6009_CR7","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/01.ju.0000169480.43557.31","volume":"174","author":"R Popat","year":"2005","unstructured":"Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005;174(3):984\u20139.","journal-title":"J Urol"},{"issue":"10","key":"6009_CR8","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3389\/fphar.2019.01618","volume":"15","author":"QQ Gong","year":"2020","unstructured":"Gong QQ, Xu YQ, Xu J, Ding XY, Guo C. Meta-analysis of randomized controlled trials using botulinum toxin A at different dosages for urinary incontinence in patients with overactive bladder. Front Pharmacol. 2020;15(10):1618.","journal-title":"Front Pharmacol"},{"issue":"3","key":"6009_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","volume":"202","author":"DJ Lightner","year":"2019","unstructured":"Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019. J Urol. 2019;202(3):558\u201363.","journal-title":"J Urol"},{"key":"6009_CR10","first-page":"100957","volume":"7","author":"E Kelsey","year":"2024","unstructured":"Kelsey E, Wynn J, Holmes A, McLeod K. Anatomical location and number of injection sites of intravesical OnabotulinumtoxinA for females with refractory idiopathic overactive bladder: a scoping review. Neurourol Urodyn. 2024;7:100957.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"6009_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.urology.2004.04.089","volume":"64","author":"GA Defreitas","year":"2004","unstructured":"Defreitas GA, Zimmern PE, Lemack GE, Shariat SF. Refining diagnosis of anatomic female bladder outlet obstruction: comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. Urology. 2004;64(4):675\u20139.","journal-title":"Urology"},{"issue":"5","key":"6009_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/nau.23124","volume":"36","author":"PF Rosier","year":"2017","unstructured":"Rosier PF, Schaefer W, Lose G, Goldman HB, Guralnick M, Eustice S, Dickinson T, Hashim H. International Continence Society Good Urodynamic Practices and Terms 2016: urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn. 2017;36(5):1243\u201360.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"6009_CR13","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","volume":"181","author":"MK Flynn","year":"2009","unstructured":"Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181(6):2608\u201315.","journal-title":"J Urol"},{"key":"6009_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1590\/S1677-55382007000200002","volume":"33","author":"DE Rapp","year":"2007","unstructured":"Rapp DE, Lucioni A, Bales GT. Botulinum toxin injection: a review of injection principles and protocols. Int Braz J Urol. 2007;33:132\u201341.","journal-title":"Int Braz J Urol"},{"issue":"4","key":"6009_CR15","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/nau.23052","volume":"36","author":"MA Avallone","year":"2017","unstructured":"Avallone MA, Sack BS, El-Arabi A, Guralnick ML, O'Connor RC. Less is more\u2014A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity. Neurourol Urodyn. 2017;36(4):1104\u20137.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"6009_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1569-9056(07)60885-9","volume":"2","author":"G Karsenty","year":"2007","unstructured":"Karsenty G, Carsenac A, Boy S, Reitz A, Bardot P, Tournebise H, et al. Botulinum toxin-A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI)-A prospective randomized study to compare 30 vs. 10 injection sites. Eur Urol Suppl. 2007;2(6):245.","journal-title":"Eur Urol Suppl"},{"issue":"6","key":"6009_CR17","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.eururo.2012.01.046","volume":"61","author":"A Coelho","year":"2012","unstructured":"Coelho A, Cruz F, Cruz CD, Avelino A. Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol. 2012;61(6):1178\u201384.","journal-title":"Eur Urol"},{"issue":"6","key":"6009_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/toxins8060164","volume":"8","author":"S-F Chen","year":"2016","unstructured":"Chen S-F, Chang C-H, Kuo H-C. Clinical efficacy and changes of urothelial dysfunction after repeated detrusor botulinum toxin A injections in chronic spinal cord-injured bladder. Toxins. 2016;8(6):164.","journal-title":"Toxins"},{"issue":"3","key":"6009_CR19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00345-008-0362-0","volume":"27","author":"U Mehnert","year":"2009","unstructured":"Mehnert U, Boy S, Schmid M, Reitz A, von Hessling A, Hodler J, Schurch B. A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol. 2009;27(3):397\u2013403.","journal-title":"World J Urol"},{"issue":"6","key":"6009_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/nau.22780","volume":"35","author":"CH Liao","year":"2016","unstructured":"Liao CH, Chen SF, Kuo HC. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: a prospective randomized comparative study. Neurourol Urodyn. 2016;35(6):717\u201323.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"6009_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/nau.22954","volume":"36","author":"P Denys","year":"2017","unstructured":"Denys P, Del Popolo G, Amarenco G, Karsenty G, Le Berre P, Padrazzi B, et al. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units Dysport\u00ae (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): a randomised placebo-controlled phase IIa study. Neurourol Urodyn. 2017;36(2):457\u201362.","journal-title":"Neurourol Urodyn"},{"key":"6009_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.urology.2019.12.001","volume":"137","author":"E Mart\u00ednez-Cuenca","year":"2020","unstructured":"Mart\u00ednez-Cuenca E, Bonillo MA, Mor\u00e1n E, Broseta E, Arlandis S. OnabotulinumtoxinA re-injection for refractory detrusor overactivity using 3\u20134 injection sites: results of a pilot study. Urology. 2020;137:50\u20134.","journal-title":"Urology"},{"issue":"6","key":"6009_CR23","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s11255-021-02802-0","volume":"53","author":"J Ton","year":"2021","unstructured":"Ton J, Downing P, Versi E, van Uem S, Ephraim S, Murphy M, Lucente V. Outcomes of a single trigone-only vs. 20 trigone-sparing injections of OnabotulinumtoxinA for refractory overactive bladder (OAB). Int Urol Nephrol. 2021;53(6):1067\u201372.","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"6009_CR24","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.eururo.2013.10.033","volume":"65","author":"A Mangera","year":"2014","unstructured":"Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2014;65(5):981\u201390.","journal-title":"Eur Urol"},{"key":"6009_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1046\/j.1526-4610.43.7s.4.x","volume":"43","author":"O Dolly","year":"2003","unstructured":"Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43:16\u201324.","journal-title":"Headache"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-024-06009-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-024-06009-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-024-06009-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T13:33:06Z","timestamp":1744810386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-024-06009-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6009"],"URL":"https:\/\/doi.org\/10.1007\/s00192-024-06009-6","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"type":"print","value":"0937-3462"},{"type":"electronic","value":"1433-3023"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Iran University of Medical Sciences, Tehran, Iran (ethics code IRCT20210214050354N1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics of Approval Statement and Clinical Trial Registration"}},{"value":"Throughout the research, the researchers adhered to the principles of the Declaration of Helsinki, ensuring the confidentiality of participants\u2019 information. All patients provided written informed consent, and no additional financial burden was imposed on them. Participants had the right to withdraw from the study at any point without affecting their medical care. This study received approval from the ethics committee of Iran University of Medical Sciences, Tehran, Iran (ethics code IRCT20210214050354N1).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Considerations"}},{"value":"The consent form was signed by all patients before the initiation of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent Statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to Reproduce Material from Other Sources"}},{"value":"None.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}